Antimicrobial Chemotherapy Conference
Producing a new antibiotic is a laborious, risky and expensive process. It typically takes 10 – 15 years and over USD 1 billion. How can we incentivise research and development (R&D) in the antibiotic field? Are current push and pull incentives enough to strengthen the antibiotic R&D pipeline and ensure patient access?
These questions and more were explored in a panel discussion at the Antimicrobial Chemotherapy Conference titled: “Are existing push and pull incentives sufficient to strengthen the antibiotic R&D pipeline and ensure treatments reach patients?” which featured the Global AMR R&D Hub’s Director, Dr Lesley Ogilvie.
The expert panel and closing remarks featured:
➜ Dr Lesley Ogilvie, Global AMR R&D Hub
➜ Mr Luka Srot, International Federation of Pharmaceutical Manufacturers and Associations
➜ Dr Rohit Malpani, Global Antibiotic R&D Partnership
➜ Dr Christopher Longshaw, Shionogi BV and Honorary Treasurer of the British Society for Antimicrobial Chemotherapy.
The Antimicrobial Chemotherapy Conference was a virtual conference jointly organised by the Global Antibiotic R&D Partnership and the British Society for Antimicrobial Chemotherapy.
To view the presentation, navigate to Session Eight on the 7 Feb tab at the Antimicrobial Chemotherapy Conference website.
